NEJM (@nejm) 's Twitter Profile
NEJM

@nejm

The New England Journal of Medicine is the world’s leading medical journal and website.

ID: 25950355

linkhttp://NEJM.org calendar_today23-03-2009 04:10:07

34,34K Tweet

934,934K Followers

430 Following

NEJM (@nejm) 's Twitter Profile Photo
NEJM
@nejm

9 months ago

In the MARIPOSA trial, researchers assessed the efficacy and safety of amivantamab–lazertinib, as compared with osimertinib, as first-line treatment in patients with advanced NSCLC with EGFR mutations. Full trial results and Plain Language Summary: nej.md/3zkBeFi

In the MARIPOSA trial, researchers assessed the efficacy and safety of amivantamab–lazertinib, as compared with osimertinib, as first-line treatment in patients with advanced NSCLC with EGFR mutations. Full trial results and Plain Language Summary: nej.md/3zkBeFi